Stanford Cardiovascular Institute, Stanford School of Medicine, Stanford, CA, USA.
Stanford Cardiovascular Institute, Stanford School of Medicine, Stanford, CA, USA; University of Puerto Rico Medical Science Campus, Rio Piedras, PR, USA.
Life Sci. 2023 Nov 1;332:122106. doi: 10.1016/j.lfs.2023.122106. Epub 2023 Sep 18.
Cancers and cardiovascular diseases are the top two causes of death in the United States. Over the past decades, novel therapies have slowed the cancer mortality rate, yet cardiac failures have risen due to the toxicity of cancer treatments. The mechanisms behind this relationship are poorly understood and it is crucial that we properly treat patients at risk of developing cardiac failure in response to cancer treatments. Currently, we rely on early-stage biomarkers of inflammation and angiogenesis to detect cardiotoxicity before it becomes irreversible. Identification of such biomarkers allows healthcare professionals to decrease the adverse effects of cancer therapies. Angiogenesis and inflammation have a systemic influence on the heart and vasculature following cancer therapy. In the field of cardio-oncology, there has been a recent emphasis on gender and racial disparities in cardiotoxicity and the impact of these disparities on disease outcomes, but there is a scarcity of data on how cardiotoxicity varies across diverse populations. Here, we will discuss how current markers of angiogenesis and inflammation induced by cancer therapy are related to disparities in cardiovascular health.
癌症和心血管疾病是美国的前两大死因。在过去几十年中，新型疗法减缓了癌症死亡率，但由于癌症治疗的毒性，心脏衰竭的发病率上升了。这种关系背后的机制尚不清楚，我们必须正确治疗有发生心脏衰竭风险的患者，以应对癌症治疗。目前，我们依赖炎症和血管生成的早期生物标志物来在心脏毒性变得不可逆转之前进行检测。识别这些生物标志物可以使医疗保健专业人员降低癌症疗法的不良反应。癌症治疗后，血管生成和炎症会对心脏和血管系统产生全身性影响。在肿瘤心脏病学领域，最近人们越来越关注心脏毒性方面的性别和种族差异，以及这些差异对疾病结局的影响，但关于不同人群中心脏毒性的差异数据却很少。在这里，我们将讨论癌症治疗引起的血管生成和炎症的当前标志物如何与心血管健康的差异相关。
